This drugmaker's stock just doubled after good news on its ovarian cancer pill
Tesaro is having a good day.
The biopharmaceutical company reported Wednesday that its drug, niraparib, improved the progression-free survival (meaning that the cancer did not get worse) in people with ovarian cancer in a 500-person phase 3 trial.
The stock was up 100% Wednesday morning.
Google Finance
Niraparib is a pill that's taken once a day, and it's part of a new kind of cancer drugs called PARP inhibitors. Essentially, they block a particular enzyme that's used by our cells to repair DNA. In certain kinds of cancer that repair system is broken allowing cancer cells to thrive, so blocking it is critical.
The drugs seem to work particularly well in people with the BRCA gene mutations, which disable other DNA repair mechanisms. For patients with these mutations, the median overall survival went up to 21 months, compared to the control group of 5.5 months.
But, Tesaro found, the drug worked not just in people with these mutations, but also in patients who didn't have the BRCA mutations but had other DNA repair problems (12.9 months, compared to 3.8 months for the control), as well as people who just didn't have the BRCA mutation (9.3 months, compared to the 3.9 months for the control).
Forbes reports that Tesaro plans to file for approval in the fourth quarter of 2016.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- Catan adds climate change to the latest edition of the world-famous board game
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- JNK India IPO allotment – How to check allotment, GMP, listing date and more
- Indian Army unveils selfie point at Hombotingla Pass ahead of 25th anniversary of Kargil Vijay Diwas